Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...
The U.S. Food and Drug Administration (FDA) recently approved ... Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable ...
21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has ... knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe sleep ...
Sleep expert Dr. Abhay Sharma talks about how Zepbound is now approved by the FDA for the treatment of moderate to severe ...
The approval is the second indication for Zepbound, which was approved for weight loss ... the new FDA green light doesn’t expand the number of people who may be eligible for the drug, since ...
Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.